Gene · 10382
TUBB4A: tubulin beta 4A class IVa
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBB4A: tubulin beta 4A class IVa. Genes, record 10382. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10382
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P04350 | Tubulin beta-4A chain | 444 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents50
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2025032204 A | 2025-03-11 | 37878 | P04350 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 37878 | P04350 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 37878 | P04350 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 4946 | P04350 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 8830 | P04350 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93592 | P04350 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93593 | P04350 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 196563 | P04350 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 196564 | P04350 | Espacenet |
| KR 1020210045575 A | 2021-04-27 | 6 | P04350 | Espacenet |
1 to 10 of 50
See all 50 patentsDrugs91
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABT-751 | CHEMBL20684 | Tubulin beta inhibitor | INHIBITOR | ChEMBL |
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 91
See all 91 drugsTrials8,740
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,740
See all 8,740 trialsNIH grants521
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBB4A papers | Newest fiscal year |
|---|---|---|---|
| R01DC011805 | Imaging genetics of laryngeal dystonia | 10 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 3 | 2025 |
| U54NS115052 | Global Leukodystrophy Initiative Clinical Trials Network (GLIA- CTN) | 3 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| R01NS058949 | Clinical, Genetic, and Cellular Consequences of Mutations In NA,K-ATPase ATP1A3 | 2 | 2025 |
| UL1TR001881 | UCLA Clinical and Translational Science Institute | 2 | 2025 |
| K01AA030083 | Mass Multivariate Derivation and Validation of AUD Biotypes using Developmental Imaging and Genomic Approaches | 1 | 2025 |
| K08NS123552 | Development of a Translational Research Platform to Understand and treat Defective Protein Trafficking in Childhood-Onset Hereditary Spastic Paraplegia | 1 | 2025 |
1 to 10 of 521Source NIH's project files
See all 521 nih grantsPapers811
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Expanding the adult spectrum of TUBB4A disease: a spasticity-tremor phenotype with network imaging correlates. | Neurogenetics | 2026 | 42760339 | PubTator, text mining | PubMed |
| Divergent somatic mutation patterns among human cerebellar neuron types. | Neuron | 2026 | 42575091 | PubTator, text mining | PubMed |
| Generation of three induced pluripotent stem cell lines from individuals with late infantile TUBB4A-associated leukodystrophy caused by a c.1172G > A (p.R391H) de novo mutation in TUBB4A. | Stem Cell Res | 2026 | 42501571 | PubTator, text mining | PubMed |
| Genotypic and phenotypic heterogeneity in tubulinopathies: insights from a Turkish multicenter cohort. | Neurol Sci | 2026 | 42472988 | PubTator, text mining | PubMed |
| The genetic landscape of childhood-onset dystonia in a nationwide Turkish cohort: Clinical spectrum, molecular diagnostics, and therapeutic implications. | Eur J Paediatr Neurol | 2026 | 42308683 | PubTator, text mining | PubMed |
| Normative modeling for quantitative brain MRI phenotyping and biomarker discovery for pediatric leukodystrophies. | medRxiv | 2026 | 42245025 | PubTator, text mining | PubMed |
| TUBB4A Is Associated with Response to Paclitaxel-Based Therapy in Esophageal Squamous Cell Carcinoma. | Tohoku J Exp Med | 2026 | 42236182 | PubTator, text mining | PubMed |
| Investigating the Function of C‑Terminal Tails of Human Tubulin Isotypes in the Motility Regulation of Cytoplasmic Dynein. | ACS Omega | 2026 | 42179625 | PubTator, text mining | PubMed |
| Performance outcomes of the PEDI-CAT for assessing functional ability in the population with leukodystrophy. | Dev Med Child Neurol | 2026 | 42060827 | PubTator, text mining | PubMed |
| Differentially expressed proteins in plasma-derived extracellular vesicles from chronic myeloid leukemia patients. | Front Genet | 2026 | 41773228 | PubTator, text mining | PubMed |
1 to 10 of 811
See all 811 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10382
GET https://conductscience.org/api/genes/v1/10382/patents?page=2